Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more
Kuros Biosciences AG (CSBTF) - Total Liabilities
Latest total liabilities as of June 2025: $33.32 Million USD
Based on the latest financial reports, Kuros Biosciences AG (CSBTF) has total liabilities worth $33.32 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kuros Biosciences AG - Total Liabilities Trend (2004–2024)
This chart illustrates how Kuros Biosciences AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kuros Biosciences AG Competitors by Total Liabilities
The table below lists competitors of Kuros Biosciences AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen SEG Co Ltd
SHE:000058
|
China | CN¥2.53 Billion |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
USA | $119.95 Million |
|
Borusan Yatirim ve Pazarlama AS
IS:BRYAT
|
Turkey | TL1.59 Billion |
|
Bank Islam Malaysia Bhd
KLSE:5258
|
Malaysia | RM94.68 Billion |
|
Elopak AS
OL:ELO
|
Norway | Nkr725.28 Million |
|
Dom Development S.A.
WAR:DOM
|
Poland | zł4.33 Billion |
|
Konoike Transport Co. Ltd
F:2KT
|
Germany | €136.30 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Kuros Biosciences AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kuros Biosciences AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kuros Biosciences AG (2004–2024)
The table below shows the annual total liabilities of Kuros Biosciences AG from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $25.79 Million | +74.82% |
| 2023-12-31 | $14.75 Million | +4.73% |
| 2022-12-31 | $14.09 Million | -1.91% |
| 2021-12-31 | $14.36 Million | +47.09% |
| 2020-12-31 | $9.76 Million | -2.34% |
| 2019-12-31 | $10.00 Million | +7.06% |
| 2018-12-31 | $9.34 Million | -27.84% |
| 2017-12-31 | $12.94 Million | +137.62% |
| 2016-12-31 | $5.45 Million | +110.27% |
| 2015-12-31 | $2.59 Million | -94.09% |
| 2014-12-31 | $43.85 Million | +20.89% |
| 2013-12-31 | $36.27 Million | +78.14% |
| 2012-12-31 | $20.36 Million | -52.08% |
| 2011-12-31 | $42.49 Million | -10.50% |
| 2010-12-31 | $47.48 Million | -21.48% |
| 2009-12-31 | $60.46 Million | -23.37% |
| 2008-12-31 | $78.89 Million | +14.13% |
| 2007-12-31 | $69.12 Million | +500.46% |
| 2006-12-31 | $11.51 Million | +37.33% |
| 2005-12-31 | $8.38 Million | +2.34% |
| 2004-12-31 | $8.19 Million | -- |